Interpreting serum procalcitonin in COVID-19 patients undergoing renal replacement therapy
Enregistré dans:
Auteurs principaux: | Briony Adams, Alec Beaney |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Elsevier
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/80209970dfdd4a6abe1e1bd1d4d8e4f6 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations
par: Kohama H, et autres
Publié: (2017) -
Disease Severity Determines Timing of Initiating Continuous Renal Replacement Therapies: A Systematic Review and Meta-Analysis
par: Zi-Jing Xia, et autres
Publié: (2021) -
Severe postoperative hyperbilirubinemia in congenital heart disease
par: Chen Xiaolan, et autres
Publié: (2021) -
Impact of Cumulative Fluid Balance During Continuous Renal Replacement Therapy on Mortality in Patients With Septic Acute Kidney Injury: A Retrospective Cohort Study
par: Jin Lin, et autres
Publié: (2021) -
Increased concentrations of procalcitonin in patients with paracetamol intoxication
par: García de Guadiana Romualdo Luis, et autres
Publié: (2021)